Cystatin B As a Tissue and Urinary Biomarker of Bladder Cancer Recurrence and Disease Progression

Adam S. Feldman,1 Jacqueline Banyard,3 Chin-Lee Wu,1,2 W. Scott McDougal,3 and Bruce R. Zetter3

Abstract

Purpose: Using proteomic techniques, we sought to identify novel protein biomarkers in tissue and urine from patients with transitional cell carcinoma (TCC).

Experimental Design: Urinary and tissue proteomes were analyzed and differentially expressed proteins were identified by mass spectrometry. One of the proteins, cystatin B, was further analyzed in TCC tissue by immunohistochemistry and in urine by semiquantitative Western blot analysis.

Results: Cystatin B tissue staining intensity significantly increased concordantly with TCC grade (P = 0.0008). Elevated urinary cystatin B levels correlated with increasing tumor grade (P = 0.062) and stage (P = 0.0047). Patients with elevated levels of cystatin B had a shorter mean ± SE time to disease recurrence (12 ± 1.82 months) compared with patients who had low levels (28.8 ± 2.26 months; P = 0.0047). Similarly, patients with elevated cystatin B levels had a shorter time to grade/stage progression compared with patients with low urinary cystatin B (P = 0.0007). By multivariate Cox regression analysis, an elevated cystatin B level was the most significant variable predicting disease recurrence (hazard ratio, 3.8; 95% confidence interval, 1.5-9.5; P = 0.0049) and grade/stage progression (hazard ratio, 10.4; 95% confidence interval, 1.6-201.5; P = 0.0104).

Conclusions: Cystatin B is elevated in tissue and urine of bladder cancer patients. Cystatin B urine levels are positively correlated with tumor grade, stage, and shorter time to disease recurrence and progression. Consequently, cystatin B may be useful as a novel predictive biomarker in TCC of the bladder.

Bladder cancer is the second most common genitourinary malignancy in the United States. In 2008, there were an estimated 68,810 newly diagnosed cases of bladder cancer and an estimated 14,100 deaths due to cancer of the bladder (1). Among all newly diagnosed cases, ~70% present as tumors without invasion into the muscularis propria (stage T1 or Tis); however, up to 50% to 70% of those cases will recur after resection and ~10% to 20% will progress to muscularis propria invasive disease (T2 or greater; ref. 2). Pathologic data, including grade, stage, and associated carcinoma in situ (CIS) at initial presentation, have provided some insight into the risk of disease progression to muscularis propria invasion (3, 4). Nevertheless, the ability to predict which patients will ultimately progress remains a significant challenge. An improved ability to accurately predict which patients will recur and ultimately progress to invasive and potentially metastatic disease would greatly enhance the ability to treat patients with bladder cancer. Such prognostic information could help tailor surveillance schedules or shift treatment algorithms to a more aggressive or conservative pathway depending on the specific risk profile of each patient.

In the molecular era, there has been a concerted effort to identify new biomarkers of invasion or risk of progression to invasive disease. Chromosomal alterations in tumor tissue samples have been observed with transitional cell carcinoma (TCC) grade and stage, with loss of 9q an early phenomenon (5), whereas loss of 17p, 3p, 13q, 18q, and 10q are found more frequently in higher-grade and higher-stage TCC (6). Tumor suppressor genes, such as p53 and Rb, have been extensively studied in bladder cancer; however, both of these markers have shown variable predictive value in assessing the risk for disease progression and survival (7). Cell cycle regulatory proteins p27 and Ki-67 may have some prognostic value for predicting recurrence and disease progression; however, further studies are necessary and these markers are not yet clinically applicable (8–10).

In this study, we applied a proteomic approach to bladder cancer biomarker discovery. We report the identification of a cathepsin protease inhibitor, cystatin B (stefin B), in bladder cancer tissue and show that cystatin B has potential as a bladder cancer biomarker in both patient tissue and urine.
Materials and Methods

Urine specimen collection and protein isolation. Under an institutional review board-approved protocol, pre-cystoscopy voided urine specimens were collected from patients who had positive findings on initial diagnostic or surveillance office cystoscopy. All TCC patients had their upper tracts cleared via either a preoperative computed tomography urogram or intraoperative retrograde pyeloureterography. Voided control urine specimens were also obtained from patients within the same age range as TCC patients. The period of urine specimen collection was from March 2003 to October 2004. Voided urine specimens were immediately cooled to 4°C and then transferred for storage at -80°C within hours. For processing, samples were thawed on ice, diluted in 1 volume of 10 mmol/L ammonium bicarbonate buffer (pH 8), supplemented with protease inhibitors, 1 mmol/L phenylmethylsulfonyl fluoride, 5 mmol/L phenanthroline, and 5 mmol/L benzamidine (Sigma-Aldrich). Samples were homogenized and fractionated into water-soluble and 2% CHAPS detergent-soluble fractions, concentrated as above, and aliquots were lyophilized.

Proteomic analysis by two-dimensional PAGE. Protein concentrations of all specimens were determined using the BCA protein assay (Pierce). Equivalent protein aliquots (10 μg) from individual urine specimens were loaded into Tg high-grade and normal control groups. Eight patients were included in each of the pooled groups. Protein (40 μg) from each of the pooled groups was reconstituted in isoelectric focusing buffer and loaded onto isoelectric focusing gel strips of pH 3 to 10 (Bio-Rad Laboratories). Protein (40 μg) from each of the tissue specimens, tumor and normal urothelium, was prepared for isoelectric focusing in a similar manner. Proteins were separated using a linear voltage ramp from 0 to 8,000 V. Gel strips were then loaded onto 10% to 20% gradient SDS-PAGE Criterion gels (Bio-Rad Laboratories) and proteins were separated by molecular weight at 185 V for 90 min. Gels were fixed in 10% methanol + 7% acetic acid, stained with SyproRuby (Bio-Rad Laboratories) overnight, and destained with the 10% methanol + 7% acetic acid solution.

Gels were imaged using a 16-bit fluorescent imaging system (ProXpress 2D Proteomic Imaging System; Perkin-Elmer) and spectra of peptide spots were analyzed and compared. Several unique peptide spots were identified. Each of these spots of interest was isolated, digested in trypsin, and prepared for analysis by liquid chromatography-tandem mass spectrometry coupled with bioinformatic processing to permit peptide sequence matching and protein identification. Liquid chromatography-tandem mass spectrometry analysis was done by the Dana-Farber/Harvard Cancer Center Cancer Proteomics Center.

Immunohistochemical staining. Immunohistochemical staining was done using a commercially available bladder cancer tissue microarray BL801 (U.S. Biomax) consisting of 37 TCC specimens and 35 normal urothelial specimens. The patient population included 26 male and 11 female TCC specimens with a mean patient age of 59.4 years (range, 37-88) and 27 male and 8 female normal control specimens from patients with mean age of 61.4 years (range, 40-88). Of the TCC specimens, 8 were grade 1, 17 were grade 2, and 12 were grade 3. Tumor grade data were provided by U.S. Biomax and determined according to the 1973 WHO grading system. These grades were confirmed by our own pathologic review (C-L.W.) of the H&E images also provided by U.S. Biomax. No staging data were available. The tissues were deparaffinized, endogenous peroxidase was blocked in 3% hydrogen peroxide in methanol, and microwave antigen retrieval was done using Antigen Unmasking Solution. Blocking was done using 5% normal horse serum and endogenous biotin was blocked using avidin/biotin kit. Tissue was incubated with mouse monoclonal anti-cystatin B/steatin B antibody, clone A6/2 (GeneTex), followed by anti-mouse biotinylated secondary antibody, amplified using ABC kit, and developed using 3,3′-diaminobenzidine. Tissue was counterstained using Gill’s hematoxylin (Sigma-Aldrich) and enhanced using Tacha’s Bluing Solution (Biocare). All reagents were purchased from Vector Laboratories, except where noted.

The specificity of the cystatin B antibody was shown with an immunohistochemistry peptide competition assay. The antibody was preincubated with either cystatin B or cystatin A peptides (R&D Systems) or bovine serum albumin (Sigma-Aldrich). Serial sections of high-grade TCC specimens obtained under institutional review board approval were stained with the peptide-competited antibody. Immunostaining was also confirmed with a second cystatin B antibody, clone M2-F1 (ab54566, Abcam).

Semi quantitative Western blot analysis. Investigation of cystatin B expression in urine was done using semiquantitative Western blot analysis of isolated protein (20 μg) from all individual urine specimens. To decrease the effect of potential variability between blots, each individual Western blot contained a mix of age-matched controls and bladder cancer patient urines. Protein from the pooled specimens and
original tumor tissue from which the protein was identified were used as positive controls. Protein isolated from the cell culture lysate of a previously described TCC cell line, MGH-U1 (11), was used as a second positive control. We have previously confirmed cystatin B expression by this cell line. The expression band from 20 μg of the same preparation of MGH-U1 total cell lysate was used as a standard to normalize each band from individual patients. Polyvinylidene difluoride membranes (Immobilon-P; Millipore) were probed for cystatin B using monoclonal anti-human cystatin B antibody, clone 225228 (R&D Systems).

The specificity of this antibody for cystatin B was confirmed by comparative Western blot analysis of specimen reactivity with cystatin A and C antibodies, clones 224705 and 197807 (R&D Systems), and antibody cross-reactivity with cystatin A and cystatin C recombinant peptides (R&D Systems).

Clinical data collection and statistical analysis. For each voided urine specimen obtained, patient clinical information included whether the patient had a new diagnosis of TCC or a prior history of disease as well as a history of prior exposure to intravesical therapy [all Bacillus Calmette-Guerin (BCG) in this cohort]. Tumor intraoperative and pathologic data were obtained following the subsequent tumor resection in that patient. These included tumor grade, tumor stage, and multifocality. Clinical data on each patient were then prospectively recorded for the entirety of our follow-up period. The period of urine specimen collection was March 2003 to October 2004. Our clinical follow-up was continued through January 2007. Clinical data included whether or not the patient received subsequent intravesical therapy, had eventual recurrent tumor, or had disease progression. Pathologic stage and grade were determined for all recurrent tumors. All specimens were reviewed by dedicated genitourinary pathologists.

Urinary cystatin B expression was first analyzed in a univariate fashion as continuous numeric data. To use urinary cystatin B level as a dichotomous variable, we performed serial testing of the urinary cystatin B mean, median, 65th percentile, and 75th percentile with the presence of a bladder tumor and with the two outcomes, time to recurrence and progression. These data were reviewed to determine the optimal cystatin B level cutpoint for this data set.

Grade, stage, and cystatin B levels in urine and tissue were analyzed using contingency table analysis with χ² test and Cochrane-Armitage test for trend across grade and stage. Kaplan-Meier time-to-event analysis was used to determine the predictive value of cystatin B for time to TCC recurrence and progression, with survival curves compared with the log-rank test (12). Univariate and multivariate Cox regression analysis was used to model risk for recurrence or grade/stage progression as a function of grade, stage, and cystatin B. Likelihood ratio tests were used to determine the significance of the Cox regression models (13). Statistical significance was achieved with a two-sided P < 0.05. Statistical analyses were done using SAS 9.1.3 and SAS JMP 7.0 software (SAS Institute).

Results

Proteomic profiling of bladder cancer. Two-dimensional PAGE proteomic profiles from high-grade TCC and normal control urine specimens were compared (Fig. 1A and B). Additionally, profiles from tissue isolated from an advanced TCC (stage T3N1M0) and from normal adjacent urothelium were compared (Fig. 1C and D). Multiple peptide spots were identified as differing between the TCC and normal control proteomes. Several of the most dramatically different proteins were excised, trypsinized, and identified by mass spectrometry. One protein of interest at approximately pI 8 to 9 MW 14 kDa in the bladder cancer tumor tissue was identified by liquid chromatography-tandem mass spectrometry as cystatin B (stefin B), an inhibitor of cathepsin family proteases.
Cystatin B is increased in bladder cancer tissue. Increased immunohistochemical cystatin B staining intensity was observed in bladder cancer tissue compared with normal bladder, and this was most distinct in high-grade TCC tissue (Fig. 2A). Some staining was observed in normal bladder, but this was largely confined to the epithelial cell layer (Fig. 2B). Immunostaining was analyzed by a pathologist blinded to the subgroups (C-L.W.). The percentage of specimens with high cystatin B intensity increased significantly with tumor grade ($P = 0.0077$, Fisher’s exact test; $P = 0.008$, Cochrane-Armitage test for trend; Fig. 2C). Cystatin B immunostaining images and clinicopathologic data for all specimens are shown in Supplementary Fig. S1 and Table S1.

Specificity of cystatin B immunoreactivity was confirmed by peptide competition. Cystatin B peptide depleted cystatin B antibody staining, whereas cystatin A peptide or bovine serum albumin control had no effect (Supplementary Fig. S2).

Urinary cystatin B correlates with TCC grade and stage. Urinary analysis was done on 51 TCC patients, with a mean age of 75 years (range, 46-76), and 28 normal controls, with a mean age of 71 years (range, 47-87). Of the TCC patients, 42 (82%) had T4 disease, 4 (8%) had T1, and 5 (10%) had T2. Fourteen (28%) were grade 1, 18 (35%) were grade 2, and 16 (31%) were grade 3, with no grade data available for 3 (6%) patients. Eighty-three percent of the TCC patients had a history of prior TCC at initial sample collection. Using semiquantitative Western blot analysis, we probed individual bladder cancer patient’s urine specimens to determine whether cystatin B was associated with TCC disease presence, tumor grade, or stage. A representative urine Western blot is shown in Fig. 3A. Samples were categorized into high or low urinary cystatin B level based on a cutoff value of $\geq 0.54$ normalized band intensity units, which was the 65th percentile of the entire population (normals + TCC). We determined that the 65th percentile was the optimal cutpoint for the outcomes recurrence and progression compared with the mean, median, and 75th percentile (data not shown). High urinary cystatin B levels ($\geq 0.54$) were found to correlate with tumor grade. As grade increased, so did the proportion of patients with elevated cystatin B ($P = 0.0242$, Fisher’s exact test; $P = 0.0062$, Cochrane-Armitage test for trend; Fig. 3B). Cystatin B levels were also significantly associated with tumor stage. With higher tumor stage, there were a greater percentage of patients with elevated cystatin B ($P = 0.0104$, Fisher’s exact test; $P = 0.0047$, Cochrane-Armitage test for trend; Fig. 3C).

Antibody specificity was addressed using Western blots containing three normal and three TCC patient urine specimens, cystatin B and A peptides, and MGH-U1 cell lysate.

Fig. 2. Immunohistochemical analysis of cystatin B expression in bladder cancer tissue. Immunohistochemical staining using cystatin B monoclonal antibody showed increased cystatin B levels in bladder cancer (A) compared with normal bladder tissue (B). A, arrow: high-grade TCC cancer cells, which are stained by the cystatin B antibody. Magnification, $\times 10$. Bar, 200 $\mu$m. C, percentage of specimens with high-intensity cystatin B staining increases concordantly with TCC grade.
Cystatin A was not detected in these urine samples, whereas cystatin C was found in both normal and TCC specimens. Elevated cystatin B levels in TCC patient urine specimens were confirmed with an additional monoclonal antibody (Supplementary Fig. S3).

**Urinary cystatin B as a marker for TCC recurrence and grade/stage progression.** We next sought to determine whether cystatin B levels were indicative of disease recurrence and stage and/or grade progression. Follow-up identified 24 (47%) patients with subsequent TCC recurrence and 23 (45%) without. Four (8%) patients had no follow-up information available. Of the 47 patients, 8 (17%) underwent grade or stage progression. Mean follow-up time for censored patients was 2.4 years, with maximum 3.6 years. Thirteen (76.5%) of 17 patients with elevated urinary cystatin B had recurrent disease compared with 12 (40%) of 30 patients with low cystatin B in the urine ($P = 0.0318$, Fisher’s exact test). Clinical and pathologic data for these patients are summarized in Table 1.

For analysis of time to recurrence, survival curves were determined using Kaplan-Meier time-to-event analysis. Patients with high cystatin B levels had an earlier time to disease recurrence compared with patients with low cystatin B levels. Patients with high cystatin B levels had a mean time to disease recurrence of 12.0 months compared with patients with low

**Table 1. Patient characteristics by urinary cystatin B level**

<table>
<thead>
<tr>
<th></th>
<th>Low cystatin B ($n = 30$)</th>
<th>High cystatin B ($n = 17$)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (range) age (y)</td>
<td>73.7 (60-89)</td>
<td>74.5 (46-96)</td>
<td>0.8322*</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>23 (77)</td>
<td>9 (53)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>7 (23)</td>
<td>8 (47)</td>
<td>0.1144</td>
</tr>
<tr>
<td>Previous TCC bladder, n (%)</td>
<td>23 (77)</td>
<td>16 (94)</td>
<td>0.2276</td>
</tr>
<tr>
<td>Prior intravesical (BCG) treatment, n (%)</td>
<td>4 (13)</td>
<td>5 (29)</td>
<td>0.2516</td>
</tr>
<tr>
<td>Tumor grade, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>12 (40)</td>
<td>2 (12)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>12 (40)</td>
<td>5 (29)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>6 (20)</td>
<td>10 (59)</td>
<td>0.0179</td>
</tr>
<tr>
<td>Tumor stage, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT1</td>
<td>28 (93.3)</td>
<td>10 (59)</td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>1 (3.3)</td>
<td>3 (18)</td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td>1 (3.3)</td>
<td>4 (23)</td>
<td>0.0152</td>
</tr>
<tr>
<td>Multifocality present tumor, n (%)</td>
<td>15 (50)</td>
<td>10 (59)</td>
<td>0.7617</td>
</tr>
<tr>
<td>BCG treatment of present tumor, n (%)</td>
<td>3 (10)</td>
<td>2 (12)</td>
<td>1.00</td>
</tr>
<tr>
<td>Mean (SD) follow-up (mo) of patients without recurrence or progression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrence analysis</td>
<td>24.9 (11.3)</td>
<td>25.6 (6.7)</td>
<td>0.8962*</td>
</tr>
<tr>
<td>Progression analysis</td>
<td>32.1 (10.5)</td>
<td>28.6 (9.0)</td>
<td>0.9084*</td>
</tr>
</tbody>
</table>

NOTE: Column percentages represent proportions of patients within low cystatin B ($n = 30$) and high cystatin B ($n = 17$) categories.

* t test.
† Fisher’s exact test.
‡ $\chi^2$ test for differences across grade and stage.
cystatin B levels who had a mean time to recurrence of 28.8 months (Fig. 4A; \( P = 0.0047 \), log-rank test).

We defined grade/stage progression as an increase in tumor grade or stage at the time of subsequent recurrence or development of locally advanced disease (\( \geq T_3 \)) or metastatic disease. Patients with high urinary cystatin B levels were more likely to undergo grade/stage progression than those with low urinary cystatin B. One (3.3\%) of 30 patients with low cystatin B progressed compared with 7 (41\%) of 17 patients with elevated cystatin B (\( P = 0.0019 \), Fisher’s exact test).

Kaplan-Meier analysis showed that patients with high cystatin B levels had an earlier time to grade/stage progression compared with patients with a low cystatin B level (\( P = 0.0007 \), log-rank test). The mean time to grade/stage progression for patients with low levels of cystatin B was 34.9 months compared with those with high levels of cystatin B with mean time to stage progression of only 18.1 months (Fig. 4B; \( P = 0.0007 \), log-rank test).

Multivariate Cox regression analysis was used to model the time to disease recurrence and grade/stage progression using cystatin B, tumor grade, tumor stage, subsequent intravesical therapy, and tumor multifocality as covariates. By univariate analysis, elevated cystatin B was the most statistically significant variable predicting time to disease recurrence, with a hazard ratio (HR) of 3.108 [95\% confidence interval (95\% CI), 1.361-7.098]. Tumor grade and stage were not found to be statistically significant predictors of disease recurrence in univariable and multivariable Cox regression analyses. When only Ta and T1 tumors were included in the model, we showed a trend toward a relationship for stage (univariate HR, 2.665; 95\% CI, 0.779-9.117; multivariate HR, 2.686; 95\% CI, 0.67-10.775) yet less so for grade (univariate HR, 0.986; 95\% CI, 0.574-1.694; multivariate HR, 1.259; 95\% CI, 0.635-2.496).

There was a trend toward an association of tumor multifocality with recurrence in both univariable and multivariable Cox proportional hazards models (univariate HR, 1.887; 95\% CI, 0.805-4.425; multivariate HR, 2.236; 95\% CI, 0.914-5.467). In the multivariable analysis, tumor multifocality was neither shown to be a confounder nor an effect modifier of cystatin B level. History of prior BCG therapy was not significantly correlated with future development of additional tumor recurrence or progression. BCG therapy for this specific tumor occurrence, however, did show an apparent protective effect against tumor recurrence in the Ta and T1 population. This protective effect was statistically significant on multivariable analysis (HR, 0.087; 95\% CI, 0.009-0.859).

High cystatin B remained a statistically significant predictor for TCC recurrence (HR, 3.558; 95\% CI, 1.378-9.189) when controlled for tumor grade, stage, multifocality, and treatment with intravesical BCG with multivariate Cox regression analysis. This relationship persisted when only those with Ta or T1 disease were included in the model (HR, 3.455; 95\% CI, 1.279-9.331) and continued to remain in the Ta population alone (HR, 3.461; 95\% CI, 1.224-9.788).

Cox regression analysis for grade/stage progression revealed that urinary cystatin B level (HR, 15.165; 95\% CI, 1.859-123.7) and tumor stage (HR, 2.894; 95\% CI, 1.375-6.090) were significant univariate predictors for progression. Although tumor grade was not a statistically significant univariate predictor of progression, there was a trend toward an association of the two (HR, 2.352; 95\% CI, 0.856-6.462). Tumor multifocality and subsequent treatment with intravesical BCG were not significant predictors of progression by univariate or multivariate analysis. By multivariate analysis, elevated urinary cystatin B was the only covariate that remained significant, with a HR of 13.145 (95\% CI, 1.366-126.5). Thus, when controlling for tumor grade, stage, multifocality, and subsequent BCG therapy, urinary cystatin B remains a significant predictor of disease grade/stage progression.

**Discussion**

In an effort to address the need for new prognostic biomarkers in bladder cancer, we used proteomic technology to identify protein changes in both TCC tissue and voided urine samples. Bladder cancer has a natural history of multifocality.
and recurrence, and the ability to identify those patients who are more likely to progress could significantly affect treatment and management strategies at the time of initial diagnosis. Protein biomarkers of disease progression may serve as indicators for earlier aggressive treatment of non-muscularis propria invasive disease or alter the algorithm for surveillance of high-risk patients. Additionally, a dependable urinary biomarker of invasive disease could prove to be a valuable complementary or alternative test to cytology and cystoscopy in the surveillance for recurrent disease.

We have identified cystatin B (stefin B) as a potential urinary and tissue biomarker for TCC of the bladder. Cystatin B is an inhibitor of cathepsin proteases (14). Many cathepsin proteases are increased in cancer (reviewed in ref. 15), and as their activity is controlled by cysteine protease inhibitors, such as cystatin B, the balance of the protease/inhibitor axis may be important. Cystatin B protein levels have been shown to correlate with tumor presence and stage in other types of cancer. In ovarian, lung, laryngeal, and hepatocellular cancers, cystatin B is up-regulated (16–19). In colorectal cancer, serum cystatin B correlates with Dukes stage and with a significantly increased risk of colorectal cancer-associated death (20). Cystatin B level also correlates with disease stage in squamous cell carcinomas of the head and neck (21).

In bladder cancer, the loss of cathepsin D correlates with increased stage, grade, and tumor morphology (22, 23). As loss of cathepsin protease activity may correspond with increased inhibitor (that is, cystatin), these results are intriguing and may be consistent with our data showing increased cystatin B levels in bladder cancer. The balance of the cathepsin/cystatin axis may vary in different tissues and tumor types; certainly, cathepsin protease expression and secretion has been shown to be different in different cell lines (24). Even greater sensitivity as a biomarker of bladder cancer may come from further studies using a combination of both cathepsin and cystatin levels.

In this study, we introduce cystatin B as a novel tissue and urine biomarker for TCC of the bladder associated with grade, stage, recurrence, and progression. Interestingly, three TCC patients who had CIS in addition to their primary tumor also had elevated cystatin B levels in their voided urine. Clinically, associated CIS increases the likelihood of progression to high-grade invasive disease. CIS is also more genetically consistent with muscularis propria invasive TCC than with noninvasive TCC (25, 26). The elevated expression of cystatin B in those with CIS further supports this protein as a marker associated with invasive TCC and risk of invasion. Our data indicate that although cystatin B may not have the specificity for TCC overall to serve as an individual diagnostic marker, it has potential as a clinically useful prognostic marker.

Elevated urinary cystatin B levels correlated with a shorter time to recurrence and a greater chance of recurring within our follow-up period. Furthermore, patients with elevated urinary cystatin B levels also had a greater risk of earlier grade/stage progression. Our multivariate analyses showed that cystatin B was the most powerful independent predictive variable for disease recurrence and progression. Tumor multifocality has been shown to be an important risk factor for disease recurrence, and tumor grade has been shown to be an important predictor of disease progression (27). The precise relationships between cystatin B and tumor grade, stage, and multifocality as predictors of disease recurrence and progression will be best determined by future validation studies on larger patient cohorts. Such predictive information regarding time to recurrence and risk of progression would greatly benefit the ability to effectively treat and monitor patients with TCC. Those patients with $T_1$ TCC at risk for a more rapid recurrence and disease progression could be followed with a more frequent schedule of surveillance, whereas those with biomarker evidence of low risk could be surveyed less frequently. Other patients with high-risk $T_1$ disease and at greater risk of progression by validated biomarkers may be more appropriately managed with aggressive surgical resection. In addition to altering surveillance and treatment algorithms, a predictive biomarker, such as cystatin B, could be helpful in stratifying patients by risk for clinical trials of current or novel therapies for TCC.

To be adopted into clinical use, new biomarkers must significantly improve the predictive ability of current nomograms. In recent years, several other promising bladder cancer biomarkers have been identified (reviewed in ref. 28). It is possible that multiplexing cystatin B with cathepsins or other urinary biomarkers, such as calreticulin (29), NMP-22 (30, 31), BLCA-4 (32, 33), or matrix metalloproteinases (34), may add significant predictive power. If these markers involve independent mechanisms of tumor pathogenesis, combining them may contribute additional sensitivity and specificity to urine cytology.

In summary, using a proteomic discovery approach, we have identified and validated increased tissue and urinary cystatin B levels in bladder cancer. We have also shown that elevated urinary cystatin B levels correlate with TCC grade and stage. Compared with conventional clinicopathologic data, elevated cystatin B is a highly significant predictor of early disease recurrence and progression.

Disclosure of Potential Conflicts of Interest

B. R. Zetter has an ownership interest in Predictive Biosciences.

Acknowledgments

We thank Peter Forbes and Dr. Dionne Graham Manning (Clinical Research Program, Children’s Hospital, Boston) for statistical consultation, Dr. Lloyd Hutchinson for helpful guidance, and Sandra Kirley for technical assistance.

References
